Endo Makes Waves with New Research on Peyronie's Disease at SMSNA Annual Meeting
Introduction
Endo, a key player in the pharmaceutical industry and a subsidiary of Mallinckrodt plc, recently made headlines with its announcement of nine new and modified presentations concerning Peyronie's disease (PD) at the Sexual Medicine Society of North America (SMSNA) Annual Meeting. Scheduled from October 9 to 12, 2025, in Malvern, Pennsylvania, these presentations are poised to change the narrative around PD, a condition affecting approximately 1 in 10 men but often shrouded in stigma and misunderstanding.
Peyronie's Disease Overview
Peyronie's disease is characterized by the development of fibrous scar tissue inside the penis, leading to a painful curvature that can significantly affect sexual function and quality of life. Despite its prevalence, many men delay seeking treatment due to embarrassment or a lack of awareness about the condition. Endo, through its product XIAFLEX®, is striving to illuminate the pathways for treatment and support for affected men.
Highlighting the Presentations
The nine presentations, which include both research findings and clinical outcomes, cover various aspects related to Peyronie's disease and the treatment with XIAFLEX®, a collagenase injection that helps reduce curvature. Among the noteworthy presentations are:
1. Understanding Peyronie's Disease Through a Women's Health Lens: This presentation features a survey assessing women's sexual health providers' practices and awareness regarding PD, reflecting the interconnectedness of sexual health issues among partners.
2. Treatment Patterns for Peyronie's Disease: This analysis reveals insights from a survey of men's healthcare providers, showcasing general treatment protocols and areas for improvement in addressing PD.
3. Collagenase Clostridium Histolyticum for Ventral Curvature: This study reports updated results from a multicenter analysis, providing further evidence for the efficacy of XIAFLEX® in treating co-morbid conditions.
4. Post Hoc Analysis of Patients with Pain: Findings demonstrate the potential for pain alleviation when using XIAFLEX® among PD patients, showcasing proactive measures for patient care.
5. Comparative Studies: Investigative research comparing collagenase treatment with surgical options to manage Peyronie’s Disease over three years reveals critical insights into current treatment efficacy.
Quotes from the Experts
Dr. Jesse N. Mills, a urologist actively involved in the presentations, expressed pride in the commitment of the medical community to shed light on PD. "I'm proud to be part of a medical community taking a closer look at Peyronie's disease, which is common but often overlooked. I believe that providers at SMSNA will be better equipped to support their patients with educational information that includes these latest data and insights."
Challenges in Diagnosis and Treatment
Despite advancements in understanding and treating Peyronie’s disease, a notable barrier remains: the reluctance of men to discuss their symptoms and seek timely medical support. This lack of communication may lead to unnecessary suffering and complications. The presentations at the SMSNA aim to bridge this gap.
The Role of XIAFLEX®
XIAFLEX® is FDA-approved for adult men with Peyronie’s disease, specifically for those presenting with palpable plaques and significant curvature. It serves not just as a treatment option but as a conversation starter about an often-ignored topic within men’s health. Importantly, the drug comes with warnings regarding potential serious side effects, emphasizing the need for comprehensive patient education.
Conclusion
Endo’s extensive focus at the SMSNA Annual Meeting marks a significant step toward increasing awareness, improving treatment protocols, and fostering open conversations about Peyronie's disease. The commitment to research and education promises to enhance the support available for those affected by PD, ultimately aiming to improve patient outcomes and encourage men to seek help without delay.
Stay tuned for further results and insights stemming from this pivotal conference, as Endo continues to lead the charge in the realm of sexual health and therapeutics.
Endo, a key player in the pharmaceutical industry and a subsidiary of Mallinckrodt plc, recently made headlines with its announcement of nine new and modified presentations concerning Peyronie's disease (PD) at the Sexual Medicine Society of North America (SMSNA) Annual Meeting. Scheduled from October 9 to 12, 2025, in Malvern, Pennsylvania, these presentations are poised to change the narrative around PD, a condition affecting approximately 1 in 10 men but often shrouded in stigma and misunderstanding.
Peyronie's Disease Overview
Peyronie's disease is characterized by the development of fibrous scar tissue inside the penis, leading to a painful curvature that can significantly affect sexual function and quality of life. Despite its prevalence, many men delay seeking treatment due to embarrassment or a lack of awareness about the condition. Endo, through its product XIAFLEX®, is striving to illuminate the pathways for treatment and support for affected men.
Highlighting the Presentations
The nine presentations, which include both research findings and clinical outcomes, cover various aspects related to Peyronie's disease and the treatment with XIAFLEX®, a collagenase injection that helps reduce curvature. Among the noteworthy presentations are:
1. Understanding Peyronie's Disease Through a Women's Health Lens: This presentation features a survey assessing women's sexual health providers' practices and awareness regarding PD, reflecting the interconnectedness of sexual health issues among partners.
2. Treatment Patterns for Peyronie's Disease: This analysis reveals insights from a survey of men's healthcare providers, showcasing general treatment protocols and areas for improvement in addressing PD.
3. Collagenase Clostridium Histolyticum for Ventral Curvature: This study reports updated results from a multicenter analysis, providing further evidence for the efficacy of XIAFLEX® in treating co-morbid conditions.
4. Post Hoc Analysis of Patients with Pain: Findings demonstrate the potential for pain alleviation when using XIAFLEX® among PD patients, showcasing proactive measures for patient care.
5. Comparative Studies: Investigative research comparing collagenase treatment with surgical options to manage Peyronie’s Disease over three years reveals critical insights into current treatment efficacy.
Quotes from the Experts
Dr. Jesse N. Mills, a urologist actively involved in the presentations, expressed pride in the commitment of the medical community to shed light on PD. "I'm proud to be part of a medical community taking a closer look at Peyronie's disease, which is common but often overlooked. I believe that providers at SMSNA will be better equipped to support their patients with educational information that includes these latest data and insights."
Challenges in Diagnosis and Treatment
Despite advancements in understanding and treating Peyronie’s disease, a notable barrier remains: the reluctance of men to discuss their symptoms and seek timely medical support. This lack of communication may lead to unnecessary suffering and complications. The presentations at the SMSNA aim to bridge this gap.
The Role of XIAFLEX®
XIAFLEX® is FDA-approved for adult men with Peyronie’s disease, specifically for those presenting with palpable plaques and significant curvature. It serves not just as a treatment option but as a conversation starter about an often-ignored topic within men’s health. Importantly, the drug comes with warnings regarding potential serious side effects, emphasizing the need for comprehensive patient education.
Conclusion
Endo’s extensive focus at the SMSNA Annual Meeting marks a significant step toward increasing awareness, improving treatment protocols, and fostering open conversations about Peyronie's disease. The commitment to research and education promises to enhance the support available for those affected by PD, ultimately aiming to improve patient outcomes and encourage men to seek help without delay.
Stay tuned for further results and insights stemming from this pivotal conference, as Endo continues to lead the charge in the realm of sexual health and therapeutics.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.